Trial Information
The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute
Inclusion Criteria:
- Cancer inpatients under the care of Dr. Follett or Dr. Candler
- Cancer inpatients to be discharged from the CCI
- Patients >18 years of age
- Patients that are taking >1 medications or herbals total at home.
Exclusion Criteria:
- Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron
patients or patients receiving radiation treatment for thyroid)
- Patients that do not remain in hospital >72 hours
- Patients without a home phone number or equivalent contact number.
- Language barrier (patients unable to speak or understand English).
- Patients that are readmitted and already included into the study.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
MRS Correlation with Treatment Response.
Outcome Description:
The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute
Outcome Time Frame:
up to 1 year
Principal Investigator
Carole Chambers, BSc. Pharmacy
Investigator Role:
Principal Investigator
Investigator Affiliation:
Alberta Health Services
Authority:
Canada: Health Canada
Study ID:
23851
NCT ID:
NCT01226589
Start Date:
October 2007
Completion Date:
October 2008
Related Keywords:
- Medication Reconciliation
- Cancer cancer
- MRS
- Treatment response
- Histologically confirmed diagnosed Breast cancer.
- Patient is 18 years or older.
- Karnofsky performance score is equal to or greater than 70.
- No previously irradiated or recurrent breast.
- No contraindication to MRS/MRI.